Antipsychotic drugs do not affect platelet 5-HT concentration in schizophrenic patients

Šagud, Marina; Nikolac, Matea; Mihaljević-Peleš, Alma; Nedić, Gordana; Vuksan Čusa, Bjanka; Mustapić, Maja; Marčinko, Darko; Jakovljević, Miro; Muck-Šeler, Dorotea; Pivac, Nela (2012) Antipsychotic drugs do not affect platelet 5-HT concentration in schizophrenic patients. Translational neuroscience, 3 . pp. 56-60. ISSN 2081-3856

| Request a personal copy from author

Abstract

Rationale: Although antipsychotic drugs are prescribed for the treatment of schizophrenia and psychotic disorders, some of these drugs are also reported to possess antidepressant properties. Therefore, they are more frequently used either as a monotherapy or as an addition to antidepressant medication treatment in depression. Objectives: The data on the effects of antipsychotic drugs on serotonin (5-hydroxytryptamine, 5-HT) transporter (5-HTT) in vivo when given to patients in therapeutic doses are still scarce. Methods: Patients with schizophrenia or schizoaffective disorders in both male and female patients, were treated with antipsychotic drugs: 25 patients received olanzapine (12.8 ± 2.8 mg/day), 14 patients were treated with typical antipsychotic, fluphenazine N=14 (10.5 ± 2.5 mg/day) and for comparison, 21 patients were treated with ziprasidone (109.0 ± 27.1 mg/day). Platelet 5-HT concentration was determined fluorimetrically and evaluated at baseline and after 28 days in 65 healthy control subjects and in 60 patients. Results: Platelet 5-HT concentration did not differ significantly [F(3, 246)=0.597 ; p=0.677] between medicationfree healthy control subjects sampled at baseline and after 28 days compared to schizophrenic patients sampled before and 28 days after antipsychotics. Tukey’s multiple comparison test revealed that treatment with fluphenazine (p=0.853), olanzapine (p=0.117), or ziprasidone (p=1.000) did not significantly alter platelet 5-HT concentration after 28 days of treatment compared to their baseline values, i.e. values before treatment. Conclusions: Although all antipsychotics used in the study possess some antidepressant effects that are assumed to be related to their serotonergic properties, and have been reported to have in vitro binding affinity for human 5-HTT, the present study failed to detect significant in vivo effects of typical (fluphenazine) or atypical (olanzapine, ziprasidone) antipsychotics on platelet 5-HT concentration in schizophrenic patients.

Item Type:	Article
Uncontrolled Keywords:	Olanzapine; Fluphenazine; Ziprasidone; Platelet serotonin; Schizophrenia
Subjects:	BIOMEDICINE AND HEALTHCARE > Clinical Medical Sciences
Divisions:	Division of Molecular Medicine
Projects:	Project title Project leader Project code Project type Molecular basis and treatment of psychiatric and stress related disorders (Molekularna podloga i liječenje psihijatrijskih i stresom izazvanih poremećaja)- Nela Pivac 098-0982522-2455 MZOS Pharmacogenomics and proteomics of serotonergic and catecholaminergic system (Farmakogenomika i proteomika serotoninskog i kateholaminskog sustava)- Dorotea Muck-Šeler 098-0982522-2457 MZOS Pharmacogenetic varability of psychiatric patients (Farmakogenetska varijabilnost u psihijatrijskih bolesnika)- Alma Mihaljević-Peleš 108-1083509-3513 MZOS Multidimensional analysis of bilogical markers in mental disorders (Multidimenzionalna analiza bioloških pokazatelja u duševnim poremećajima)- Miro Jakovljević 108-1080037-0323 MZOS
Depositing User:	Matea Nikolac Perković
Date Deposited:	04 Dec 2015 08:44
URI:	http://fulir.irb.hr/id/eprint/2374
DOI:	10.2478/s13380-012-0001-5

Actions (login required)

View Item